Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used six whole-exome-sequenced primary HGSOC/USC cell-lines and three xenografts overexpressing HER2/neu and harboring mutated or wild-type PIK3CA/PIK3R1 genes to evaluate the role of PI3K-mutations as potential mechanism of resistance to afatinib, an FDA-approved pan-c-erb-inhibitor in clinical trials in USC.
|
30630630 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
|
31284467 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.
|
30925458 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
|
31128298 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas.
|
31752654 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Notably, peptide 17, a YAP inhibitor, exerted a significant attenuating effect on OC progression by diminishing the activation of the PI3K/Akt/mTOR pathway in vitro as well as in vivo.
|
31638241 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR signaling pathway is considered as a promising therapeutic target in the treatment of ovarian cancer (OC); however, inhibition of this pathway only exhibited moderate clinical efficacy when tested clinically.
|
30972187 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
|
30755818 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic changes of genes of the PI3K pathway are one of the potential genetic determinants of ovarian carcinomas.
|
31731647 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Likewise, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is also a central regulator of the ovarian cancer.
|
29401696 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
|
29930760 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.
|
29743815 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we identified the molecular mechanism that limits the efficacy of the beta-sparing PI3Ki, Taselisib (GDC0032), in PIK3CA-mutated OC cell lines (IGROV1 and OAW42) that acquired resistance to GDC0032.
|
30237504 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.
|
29909423 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggested that PI3K induced epithelial-to-mesenchymal transition and promoted cell migration and invasion by activating the PI3K/AKT pathway in ovarian cancer.
|
30245957 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the FOXM1 signaling pathway and the PI3K/AKT/mTOR signaling pathway is associated with poor prognosis in ovarian cancer.
|
30129654 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer.
|
29371953 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer.
|
29113199 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAF: cancer-associated fibroblasts; COG: Cluster of Orthologous Groups; DEA: disease enrichment analysis; EOC: epithelial ovarian carcinoma; ESCC: oesophageal squamous cell carcinoma; GSI: gamma secretase inhibitor; GO: Gene Ontology; GSEA: gene set enrichment analyzes; HAS: Hungarian Academy of Sciences; lncRNAs: long non-coding RNAs; MAPK/ERK: mitogen-activated protein kinase/extracellular signal-regulated kinases; NGS: next-generation sequencing; ncRNAs: non-coding RNAs; OvC: ovarian cancer; PI3K/Akt/mTOR: phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin; RT-PCR: real-time polymerase chain reaction; SNP: single nucleotide polymorphism; TF: transcription factor; TGF-β: transforming growth factor-β.
|
28574782 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proteomic analysis reveals that PI3K/mTOR inhibition in HGS-OvCa patient-derived xenografts induces both pro-apoptotic and anti-apoptotic signaling responses that limit cell killing, but also primes cells for inhibitors of anti-apoptotic proteins.
|
28848242 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, reduced expression of miRNA‑21 replicated the effect of celastrol on OVCAR3 cells and inhibited the PI3K/p‑Akt‑NF‑κB signaling pathway in an in vitro model of ovarian carcinoma.
|
27840916 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
|
26983899 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
|
27082164 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggested that combined inhibition of PI3K and PARP may be an effective therapeutic strategy for ovarian cancers with PIK3CA mutations and that the accompanied BRCA downregulation following PI3K inhibition could serve as a biomarker for the effective response to PARP inhibition.
|
26909613 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-targeting IKKβ and PI3K pathways downstream of GAB2 might be a promising therapeutic strategy for ovarian cancer that overexpresses GAB2.
|
26657155 |
2016 |